Comparison of multiple-dose and once-daily nitrate therapy in patients with stable angina pectoris: Effects on quality-of-life indices

Current Therapeutic Research - Clinical and Experimental

Volumn 57, Issue 12, 1996, Pages 927-936

  Niemeyer, Menco G ^a   Kleinjans, Huub A J ^b   De Ree, Rob ^b   Zwinderman, Aeilko H ^c   Cleophas, Ton J M ^d   Van Der Wall, Ernst E ^c  

^a MARTINI HOSPITAL   (Netherlands)

^b Medical Department   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d Merwede Ziekenhuis   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; NITRATE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; EXERCISE TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RELIABILITY; SUBLINGUAL DRUG ADMINISTRATION; SYMPTOM; WELLBEING;

EID: 0030483419     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(96)80111-1     Document Type: Article

References (32)

1. Morris JL, Cowan JC. Nitrates in myocardial infarction: A current perspective. Can J Cardiol. 1995;11(Suppl 1):5B-10B.
2. Jugdutt BJ. Nitrates in myocardial infarction: A review. Cardiovasc Drugs Ther. 1994; 8:635-646.
3. Anonymous. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano po lo Studio della Soppravivenza nell' infarto Miocardico. Lancet. 1994; 343:1115-1122.
4. Anonymous. ISIS-4: A randomised factorial trial assessing only oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Fourth International Study of Infarct Survival. Lancet. 1995;345: 669-685.
5. Cleophas TJM, Niemeyer MG, van der Wall EE, van der Meulen J, on behalf of the ISMN study group. Nitrate-induced headache in patients with stable angina pectoris: Beneficial effect of starting on a low dosage. Angiology. 1996;47:825-835.
6. Abshagen U, Spörl-Radun S. First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. Eur J Clin Pharmacol. 1981;19:423-429.
7. Spörl-Radun S, Betzien G, Kaufmann B. Effects and pharmacokinetics of isosorbide dinitrate in normal man. Eur J Clin Pharmacol. 1980;18:237-244.
8. Nijberg G, Carlens P, Lindström E. The effect of isosorbide-5-mononitrate (5-ISMN) Durules on exercise tolerance in patients with exertional angina pectoris. A placebo controlled study. Eur Heart J. 1986;7:835-842.
9. Parker JO, Wisenberg G. Antianginal effects of sustained release isosorbide-5-mononitrate (ISMN). Circulation. 1989;80(Suppl II):267-268.
10. Nordlander R. Can nitrate tolerance be avoided with once-daily administration of isosorbide-5-mononitrate 60 mg in Durules? Eur Heart J. 1989;10(Suppl):73-74.
11. Lemmer D, Scheidel B, Blume H, Becker HJ. Clinical chronopharmacology of oral sustained-release isosorbide-5-mononitrate in healthy subjects. Eur J Clin Pharmacol. 1991; 40:71-75.
12. Scheidel B, Lenhard G, Blume H, et al. Chronopharmacology of isosorbide-5-mononitrate (immediate release, retard formulation) in healthy subjects. Eur J Clin Pharmacol. 1989;36(Suppl):177-178.
13. Marquis P, Fagol C, Joire JE. Clinical validation of a quality of life questionnaire in angina pectoris patients. Eur Heart J. 1995;16:1554-1560.
14. Blackwelder WC. Providing the null hypothesis in clinical trials. Control Clin Trials. 1982;3:345-353.
15. Lee ML, Lusher JM. The problem of therapeutic equivalence with paired qualitative data: An example from a clinical trial using haemophiliacs with an inhibitor to factor VIII. Stat Med. 1991;10:433-441.
16. Cleophas TJM, Tavenier P. Fundamental issues of choosing the right type of trial. Am J Ther. 1994;1:327-332.
17. Cleophas TJM. A simple analysis of crossover studies with one-group interaction. Int J Clin Pharmacol Ther. 1995;32:322-328.
18. Cleophas TJM. Underestimation of treatment effect in crossover trials. Angiology. 1990; 41:673-679.
19. Louis TA, Lavori PW, Bailar JC, Polansky M. Crossover and self-controlled designs in clinical research. NEJM. 1984;310:24-31.
20. Stewart AH, Hays RD, Ware JE. The MOS Short-Form General Health Survey: Reliability and validity in a patient population. Med Care. 1988;26:724-735.
21. Wiklund J, Comerfold MB, Dimenas E. The relationship between exercise tolerance and quality of life in angina pectoris. Clin Cardiol. 1991;14:204-208.
22. Dupuy HJ. The psychological general well-being index. In: Wenger NK, Matson ME, Furberg CD, Elinson J, eds. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York: Le Jaq Publishing; 1984:170-183.
23. Testa MA, Simonson DC. Assessment of quality of life outcomes. NEJM. 1996;334:835-840.
24. Zwinderman AH. Response models with manifest predictors. In: van der Linden W, Hambleton RK, eds. Handbook of Modern Item Response Theory. Berlin: Springer Verlag; 1996:175-195.
25. Nunnually JC. Cronbach's alpha. In: Nunnually JC, ed. Psychometric Theory. 2nd ed. New York: McGraw-Hill; 1978:76-96.
26. Walldius G, Regnström J, Nilsson J, et al. The Probucol Quantitative Regression Swedish Trial. Am J Cardiol. 1993;71:15-19.
27. Quyyami AA, Panza AA, Diodati JG, et al. Prognostic implications of myocardial ischemia during daily life in low risk patients with coronary artery disease. J Am Coll Cardiol. 1993;21:700-708.
28. Cleophas TJM, van der Mey N, van der Meulen J, Niemeyer MG. Quality of life before and during antihypertensive treatment: A comparative study of celiprolol and atenolol. Angiology. 1996;47:1001-1009.
29. Hunt S, McKenna SP, McEwen J. The Nottingham Health Profile User's Manual. Manchester: Galen Research and Consultancy; 1989.
30. Brazier JE, Harper B, Jones NMB, et al. Validating the SF-36 health survey questionnaire: New outcome measure for primary care. BMJ. 1992;305:160-164.
31. Laupacis A, Wong C, Churchill D. The use of generic and specific quality-of-life measures in haemodialysis patients treated with erythropoietin. Control Clin Trials. 1991;12:168-179.
32. Meenan RM, Anderson JJ, Kuzis LE. Outcome assessment in clinical trials: Evidence for the sensitivity of a health status measure. Arthritis Rheum. 1984;27:1344-1351.